All News

6 January 2025

China’s National Medical Products Administration (NMPA) Approves VYLOY™ (zolbetuximab) for First-Line Treatment of Advanced Gastric or Gastroesophageal Junction AdenocarcinomaAntibodies

4 January 2025

Chime Biologics and Mabgeek Achieve MG-K10 PPQ Milestone, Advancing Atopic Dermatitis and Asthma Therapies Antibody Drug MG-K10 Late-Stage Clinical Trials and CommercializationAntibodies

3 January 2025

Combination of Poolbeg and HOOKIPA Pharma Inc.More News

3 January 2025

Hanx Biopharmaceuticals, Ltd. Announces First Patient Dosing in First-in-Human Phase 1 Clinical Trial of HX044Antibodies

2 January 2025

Innovent Enters into Exclusive Global License Agreement with Roche for Novel DLL3 Antibody Drug ConjugateAntibodies

2 January 2025

Atavistik Bio Announces Research Collaboration with Pfizer to Accelerate Discovery of Novel Precision Allosteric TherapeuticsMore News

2 January 2025

Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular DystrophyDNA RNA and Cells

1 January 2025

Brii Bio Announces Signing of Asset Purchase Agreements Acquiring BRII-179 IP Rights and Completed Patient Enrollment for ENRICH StudyVaccines

1 January 2025

CARsgen Announces the Initiation of an Investigator-Initiated Trial for an Allogeneic CD19/CD20 CAR-T TherapyDNA RNA and Cells

1 January 2025

Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNAMore News

31 December 2024

Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With HypercortisolismSmall Molecules

31 December 2024

Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian CancerSmall Molecules

31 December 2024

Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene FitelparvovecDNA RNA and Cells

31 December 2024

Duality Biologics Announces B7H4 ADC Milestone Achievement and License Exercise by BeiGeneAntibodies

30 December 2024

Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.More News

30 December 2024

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory PapillomatosisDNA RNA and Cells

30 December 2024

CARsgen Announces Positive Topline Results from China GC/GEJ Pivotal Phase II Clinical Trial of Claudin18.2 CAR-T (Satri-cel)Antibodies

30 December 2024

Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer ImagingAntibodies

30 December 2024

IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid TumorsAntibodies

30 December 2024

Huadong Medicine Co., Ltd. and SynerK reached a strategic cooperation to jointly develop a novel siRNA drug SNK-2726More News

30 December 2024

Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMADNA RNA and Cells

30 December 2024

European Commission approves RYBREVANT®▼ (amivantamab) in combination with LAZCLUZE®▼ (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancerAntibodies

30 December 2024

U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2Antibodies

27 December 2024

TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with ChemotherapyAntibodies

27 December 2024

DATROWAY® Approved in Japan as the First TROP-2 Directed Therapy for Patients with Previously Treated Unresectable or Recurrent HR Positive, HER2 Negative Breast CancerAntibodies

27 December 2024

argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating PolyneuropathyAntibodies

26 December 2024

Preliminary Results of Qilu Pharmaceutical’s Phase Ia Study on GPRC5D/CD3-Targeting Bispecific Antibody QLS32015 Unveiled at 2024 ASH Annual MeetingAntibodies

26 December 2024

Axcelead DDP Enters into Drug Discovery Service Agreement with Astellas for Targeted Protein DegradersMore News

24 December 2024

Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily WithdrawnAntibodies

23 December 2024

Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAMEAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

CD73 Inhibitor Pipeline Review

CD38-Targeted Antibody & Cell Therapy Pipeline Review

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review

2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

B7-H4 Targeted Antibody Therapy Pipeline Review

Report Package: “Drug the Undruggable” Technologies

CCR8-Targeted Antibody Immunotherapy Pipeline Review

Blockbuster Biologics 2019: Sales of Recombinant Therapeutic Antibodies & Proteins

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective